CN102309635B - 一种治疗糖尿病的中药制剂 - Google Patents
一种治疗糖尿病的中药制剂 Download PDFInfo
- Publication number
- CN102309635B CN102309635B CN 201110266670 CN201110266670A CN102309635B CN 102309635 B CN102309635 B CN 102309635B CN 201110266670 CN201110266670 CN 201110266670 CN 201110266670 A CN201110266670 A CN 201110266670A CN 102309635 B CN102309635 B CN 102309635B
- Authority
- CN
- China
- Prior art keywords
- parts
- folium
- chinese medicine
- diabetes
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 241000758797 Pterocarya Species 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 238000007580 dry-mixing Methods 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 33
- 210000004369 blood Anatomy 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 30
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 244000252337 Epipremnum pinnatum Species 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 244000294611 Punica granatum Species 0.000 abstract 1
- 235000014360 Punica granatum Nutrition 0.000 abstract 1
- 241000124033 Salix Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 239000008103 glucose Substances 0.000 description 22
- 230000006870 function Effects 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 206010020710 Hyperphagia Diseases 0.000 description 10
- 208000004880 Polyuria Diseases 0.000 description 10
- 206010016256 fatigue Diseases 0.000 description 10
- 208000022530 polyphagia Diseases 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 9
- 206010036067 polydipsia Diseases 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 229940100389 Sulfonylurea Drugs 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 4
- 201000008980 hyperinsulinism Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 229940122069 Glycosidase inhibitor Drugs 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003316 glycosidase inhibitor Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000004203 pancreatic function Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 240000009087 Crescentia cujete Species 0.000 description 1
- 235000005983 Crescentia cujete Nutrition 0.000 description 1
- 241000233779 Cyclocarya paliurus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 1
- 241000413224 Luisia Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000052651 Pancreatic hormone Human genes 0.000 description 1
- 101800001268 Pancreatic hormone Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001504624 Streptopelia Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 201000008496 endemic goiter Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 229940032957 pancreatic hormone Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110266670 CN102309635B (zh) | 2011-09-09 | 2011-09-09 | 一种治疗糖尿病的中药制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110266670 CN102309635B (zh) | 2011-09-09 | 2011-09-09 | 一种治疗糖尿病的中药制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102309635A CN102309635A (zh) | 2012-01-11 |
CN102309635B true CN102309635B (zh) | 2013-04-10 |
Family
ID=45423444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110266670 Active CN102309635B (zh) | 2011-09-09 | 2011-09-09 | 一种治疗糖尿病的中药制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102309635B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772660A (zh) * | 2012-07-11 | 2012-11-14 | 北京阳光一佰生物技术开发有限公司 | 新型同时降血脂和降血糖的中药组合物及其制法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101953992B (zh) * | 2009-07-13 | 2012-01-25 | 李文艳 | 一种治疗糖尿病的药物 |
CN101904994B (zh) * | 2010-07-16 | 2011-11-09 | 赵双全 | 治疗糖尿病的中药制剂 |
-
2011
- 2011-09-09 CN CN 201110266670 patent/CN102309635B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102309635A (zh) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102274429B (zh) | 一种治疗糖尿病的中药组合物 | |
CN101708295A (zh) | 一种治疗糖尿病的中药制剂及其制备方法 | |
CN102366595B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN101428113A (zh) | 一种治疗2型糖尿病的中药制剂及其制备方法 | |
CN103768407B (zh) | 一种复方降糖胶囊及其制备方法 | |
CN101085039B (zh) | 一种预防和治疗糖尿病(高血糖)的组合物及其制备方法 | |
CN102309635B (zh) | 一种治疗糖尿病的中药制剂 | |
CN117599125A (zh) | 一种用于治疗骨质疏松症的补钙壮骨中药组合物及制法和应用 | |
CN102631482B (zh) | 一种具有防治糖尿病及并发症的中药组合物 | |
CN101024037A (zh) | 治疗非胰岛素依赖型糖尿病的药物 | |
CN102366540B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN102366480B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN103751558B (zh) | 一种复方降糖丸剂及其制备方法 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN102552677B (zh) | 黄地安消胶囊及其制备方法 | |
CN102145059B (zh) | 治疗难治性高血压的中成药 | |
CN104689151A (zh) | 一种治疗糖尿病的中药组合物及其用途 | |
CN105168892A (zh) | 一种用于治疗低血糖症的中药制剂及制备方法 | |
CN1263488C (zh) | 双参胶囊及其制备工艺 | |
CN111166860A (zh) | 一种治疗糖尿病的中药组合物及中药汤剂和应用 | |
CN102366481B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN102366596B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN103656467A (zh) | 用于糖尿病的辅助治疗药物 | |
CN102366443B (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN114588228B (zh) | 一种治疗2型糖尿病的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine prepn for treating diabetes Effective date of registration: 20130827 Granted publication date: 20130410 Pledgee: Liuzhou Rural Credit Cooperative Association Pledgor: GUANGXI ZHENGTANG PHARMACEUTICAL PRODUCT Co.,Ltd.|Liu Jingming Registration number: 2013450000006 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20140912 Granted publication date: 20130410 Pledgee: Liuzhou Rural Credit Cooperative Association Pledgor: GUANGXI ZHENGTANG PHARMACEUTICAL PRODUCT Co.,Ltd.|Liu Jingming Registration number: 2013450000006 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine prepn for treating diabetes Effective date of registration: 20140918 Granted publication date: 20130410 Pledgee: Liuzhou Rural Credit Cooperative Association Pledgor: GUANGXI ZHENGTANG PHARMACEUTICAL PRODUCT Co.,Ltd.|Liu Jingming Registration number: 2014450000002 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160802 Granted publication date: 20130410 Pledgee: Liuzhou Rural Credit Cooperative Association Pledgor: GUANGXI ZHENGTANG PHARMACEUTICAL PRODUCT Co.,Ltd.|Liu Jingming Registration number: 2014450000002 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine prepn for treating diabetes Effective date of registration: 20161123 Granted publication date: 20130410 Pledgee: Liuzhou Rural Credit Cooperative Association Pledgor: GUANGXI ZHENGTANG PHARMACEUTICAL PRODUCT Co.,Ltd.|Liu Jingming Registration number: 2016450000016 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210526 Granted publication date: 20130410 Pledgee: Liuzhou Rural Credit Cooperative Association Pledgor: GUANGXI ZHENGTANG PHARMACEUTICAL PRODUCT Co.,Ltd.|Liu Jingming Registration number: 2016450000016 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine preparation for treating diabetes Effective date of registration: 20210615 Granted publication date: 20130410 Pledgee: Liuzhou Rural Credit Cooperative Association Pledgor: GUANGXI ZHENGTANG PHARMACEUTICAL PRODUCT Co.,Ltd.|Liu Jingming Registration number: Y2021450000022 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231012 Granted publication date: 20130410 Pledgee: Liuzhou Rural Credit Cooperative Association Pledgor: GUANGXI ZHENGTANG PHARMACEUTICAL PRODUCT Co.,Ltd.|Liu Jingming Registration number: Y2021450000022 |